Dataset Information

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer.

ABSTRACT:

Background

Combinations of exercise and nutritional interventions might improve the functional prognosis for cachectic cancer patients. However, high attrition and poor compliance with interventions limit their efficacy. We aimed to test the feasibility of the early induction of new multimodal interventions specific for elderly patients with advanced cancer Nutrition and Exercise Treatment for Advanced Cancer (NEXTAC) programme.

Methods

This was a multicentre prospective single-arm study. We recruited 30 of 46 screened patients aged ?70 years scheduled to receive first-line chemotherapy for newly diagnosed, advanced pancreatic, or non-small-cell lung cancer. Physical activity was measured using pedometers/accelerometer (Lifecorder^® , Suzuken Co., Ltd., Japan). An 8 week educational intervention comprised three exercise and three nutritional sessions. The exercise interventions combined home-based low-intensity resistance training and counselling to promote physical activity. Nutritional interventions included standard nutritional counselling and instruction on how to manage symptoms that interfere with patient's appetite and oral intake. Supplements rich in branched-chain amino acids (Inner Power^® , Otsuka Pharmaceutical Co., Ltd., Japan) were provided. The primary endpoint of the study was feasibility, which was defined as the proportion of patients attending ?4 of six sessions. Secondary endpoints included compliance and safety.

Results

The median patient age was 75 years (range, 70-84). Twelve patients (40%) were cachectic at baseline. Twenty-nine patients attended ?4 of the six planned sessions (96.7%, 95% confidence interval, 83.3 to 99.4). One patient dropped out due to deteriorating health status. The median proportion of days of compliance with supplement consumption and exercise performance were 99% and 91%, respectively. Adverse events possibly related to the NEXTAC programme were observed in five patients and included muscle pain (Grade 1 in two patients), arthralgia (Grade 1 in one patient), dyspnoea on exertion (Grade 1 in one patient), and plantar aponeurositis (Grade 1 in one patient).

Conclusions

The early induction of multimodal interventions showed excellent compliance and safety in elderly patients with newly diagnosed pancreatic and non-small-cell lung cancer receiving concurrent chemotherapy. We are now conducting a randomized phase II study to measure the impact of these interventions on functional prognosis.

SUBMITTER: Naito T

PROVIDER: S-EPMC6438328 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer.

Naito Tateaki T Mitsunaga Shuichi S Miura Satoru S Tatematsu Noriatsu N Inano Toshimi T Mouri Takako T Tsuji Tetsuya T Higashiguchi Takashi T Inui Akio A Okayama Taro T Yamaguchi Teiko T Morikawa Ayumu A Mori Naoharu N Takahashi Toshiaki T Strasser Florian F Omae Katsuhiro K Mori Keita K Takayama Koichi K

Journal of cachexia, sarcopenia and muscle 20181018 1

<h4>Background</h4>Combinations of exercise and nutritional interventions might improve the functional prognosis for cachectic cancer patients. However, high attrition and poor compliance with interventions limit their efficacy. We aimed to test the feasibility of the early induction of new multimodal interventions specific for elderly patients with advanced cancer Nutrition and Exercise Treatment for Advanced Cancer (NEXTAC) programme.<h4>Methods</h4>This was a multicentre prospective single-ar ...[more]

PMID: 30334618

Similar Datasets

Project description:Currently, immunotherapy is widely used in the treatment of various stages of non-small cell lung cancer. According to clinical experience and results of previous studies, immunotherapy as neoadjuvant therapy seems to exhibit better efficacy against early resectable non-small cell lung cancer as compared to advanced lung cancer, which is often defined as unresectable non-small cell lung cancer. However, this observation has not been established in clinical studies. This systematic review aimed to evaluate the efficacy of immunotherapy in early and late lung cancer, wherein objective response rate (ORR) and disease control rate (DCR) were used as evaluation indexes. The present study also evaluated the safety of immunotherapy in early and late lung cancer, wherein the rate of treatment-related adverse reactions (TRAEs) was used as an indicator. Electronica databases, including PubMed, Cochrane Library, Embase, and other databases, were searched to identify relevant studies. Besides this, all the available reviews, abstracts, and meeting reports from the main international lung cancer meetings were searched manually. ORR, DCR, and TRAEs were extracted as the primary outcomes. A total of 52 randomized controlled trials involving 13,660 patients were shortlisted. It was observed that immunotherapy alone significantly improved DCR in early lung cancer in comparison to advanced lung cancer. Importantly, the improvement in ORR was not to the same extent as reported in the case of advanced lung cancer. The combination of immunotherapy with other therapies, especially immunochemotherapy, significantly improved ORR and DCR in early lung cancer. In terms of safety, immunotherapy either alone or in combination with other therapies exhibited a better safety profile in early lung cancer than in advanced lung cancer. Altogether, the benefits of immunotherapy in early lung cancer appeared to be better than those observed in advanced lung cancer, especially with the regard to the regimen of immunotherapy in combination with chemotherapy. In terms of safety, both immunotherapy alone and its combination with chemotherapy were found to be safer in early lung cancer as compared to advanced lung cancer.

Project description:Simple Summary The treatment of advanced non-small cell lung cancer (NSCLC) after the age of 65 raises age-related problems as the elderly are often affected by other diseases, not infrequently chronic, take drugs that may interfere with anti-cancer treatment and are sometimes unable to fully understand relevant information. Moreover, they do not represent the ideal patient for enrolment in clinical trials, even with immunotherapy, which is now the choice therapy for the first-line treatment of NSCLC. With a view to offering more time to patients with metastatic NSCLC, the issues of quality of life and appropriateness of oncological care in the elderly are of primary importance. This review stresses the need to find a common approach to lung cancer management in a steadily aging society and describes the main currently available data on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, confirming the necessity for reliable biomarkers that predict immune response to assess which patients benefit from which type of immunotherapy. Abstract Immune checkpoint inhibitors have changed the history of NSCLC treatment by becoming, alone or in combination with platinum-based chemotherapy, a mainstay of first-line therapy for advanced NSCLC. This increasingly dictates the identification of predictive biomarkers of response that can guide patient selection, in order to rationalize and personalize therapies, particularly in elderly patients. Immunotherapy in these patients raises questions of efficacy and tolerability related to aging, which is accompanied by a progressive decline in various body functions. Physical, biological and psychological changes contribute to individual validity status and, preferably, ‘fit’ patients are generally enrolled in clinical trials. In elderly patients, especially frail and complex patients with more than one chronic disease, data are poor and specific prospective studies are needed. This review reports the main available results on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, in terms of efficacy and toxicity, and aims to highlight the need to better predict which patients might benefit from immunotherapy agents by probing knowledge and integrating information on immune system changes and age-related physiopathological modifications.

Dataset Information

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer.

Background

Methods

Results

Conclusions

Publications

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets